PL1797871T3 - Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania - Google Patents

Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania

Info

Publication number
PL1797871T3
PL1797871T3 PL05792179T PL05792179T PL1797871T3 PL 1797871 T3 PL1797871 T3 PL 1797871T3 PL 05792179 T PL05792179 T PL 05792179T PL 05792179 T PL05792179 T PL 05792179T PL 1797871 T3 PL1797871 T3 PL 1797871T3
Authority
PL
Poland
Prior art keywords
preparation
receptor agonist
release formulation
formulation containing
dopamine receptor
Prior art date
Application number
PL05792179T
Other languages
English (en)
Inventor
Luping Zhang
Original Assignee
Shandong luye pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong luye pharmaceutical co ltd filed Critical Shandong luye pharmaceutical co ltd
Publication of PL1797871T3 publication Critical patent/PL1797871T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05792179T 2004-09-21 2005-09-21 Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania PL1797871T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410077961 2004-09-21
EP05792179.3A EP1797871B1 (en) 2004-09-21 2005-09-21 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
PCT/CN2005/001521 WO2006032202A1 (fr) 2004-09-21 2005-09-21 Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation

Publications (1)

Publication Number Publication Date
PL1797871T3 true PL1797871T3 (pl) 2015-07-31

Family

ID=36089849

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05792179T PL1797871T3 (pl) 2004-09-21 2005-09-21 Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania

Country Status (9)

Country Link
US (2) US8691277B2 (pl)
EP (1) EP1797871B1 (pl)
JP (1) JP5081622B2 (pl)
KR (1) KR20070059161A (pl)
AU (1) AU2005287743B2 (pl)
CA (1) CA2581143C (pl)
ES (1) ES2536460T3 (pl)
PL (1) PL1797871T3 (pl)
WO (1) WO2006032202A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
KR101446813B1 (ko) * 2006-04-06 2014-10-01 뉴파쎄 인크. 도파민 연관된 상태의 치료를 위한 이식체
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
EP2035002A1 (en) * 2006-06-16 2009-03-18 Solvay Pharmaceuticals B.V. Combination preparations comprising slv308 and a l-dopa
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
WO2009152041A2 (en) * 2008-06-09 2009-12-17 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
CA2738414C (en) 2008-09-29 2014-05-27 Wockhardt Research Centre Extended release dosage form of ropinirole
FR2936710B1 (fr) * 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
AU2010266285A1 (en) * 2009-07-02 2012-02-09 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
ES2572948T3 (es) * 2010-11-25 2016-06-03 Shan Dong Luye Pharmaceutical Co., Ltd. Composiciones de rotigotina o sales farmacéuticamente aceptables de rotigotina
EP2646009A1 (en) * 2010-12-02 2013-10-09 Ratiopharm GmbH Rotigotine ionic liquid
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
US20190374534A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물
WO2025243901A1 (ja) * 2024-05-21 2025-11-27 株式会社 SENTAN Pharma 注射製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
JP2651320B2 (ja) 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
JPH10167968A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd マイクロパーティクルの製造法
CA2267930A1 (en) 1996-10-09 1998-04-16 Nobuyuki Takechi A method for producing a microparticle
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
JP3663271B2 (ja) * 1997-01-24 2005-06-22 シュバルツ ファルマ アクチェンゲゼルシャフト 新規の分枝鎖エステル及びその製法
WO2000003660A1 (en) * 1998-07-17 2000-01-27 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
OA11728A (en) * 1998-12-16 2005-02-01 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.
GB9828861D0 (en) * 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
DE60030828T2 (de) 1999-07-09 2007-02-08 Bts Holding International Bv Optische abtastvorrichtung mit umschaltbarer auflösung
US7011776B2 (en) 2000-04-28 2006-03-14 Tanabe Seiman Co., Ltd. Method and apparatus for preparing microspheres
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
BR0209198A (pt) * 2001-04-26 2004-06-08 Control Delivery Sys Inc Métodos de sìntese de compostos contendo fenol
CA2506319C (en) * 2002-11-18 2012-08-28 Polymerix Corporation Stents comprising biodegradable polymers associated with therapeutic agents
SI1610791T1 (sl) 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen

Also Published As

Publication number Publication date
US8691277B2 (en) 2014-04-08
US9220782B2 (en) 2015-12-29
JP5081622B2 (ja) 2012-11-28
US20080260846A1 (en) 2008-10-23
JP2008513524A (ja) 2008-05-01
EP1797871A1 (en) 2007-06-20
WO2006032202A1 (fr) 2006-03-30
AU2005287743A1 (en) 2006-03-30
EP1797871A4 (en) 2012-11-28
ES2536460T3 (es) 2015-05-25
HK1107012A1 (en) 2008-03-28
CA2581143A1 (en) 2006-03-30
CA2581143C (en) 2015-03-31
AU2005287743B2 (en) 2011-09-29
EP1797871B1 (en) 2015-02-25
KR20070059161A (ko) 2007-06-11
US20140255488A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
IL184167A0 (en) Compositions comprising anti-igf-1 receptor antibodies and methods for obtaining said antibodies
IL183384A0 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
IL183541A0 (en) Toll like receptor 3 antagonists, methods and uses
HUP0401191A3 (en) Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
AU2003238597A8 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
ZA200803668B (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
IL209402A (en) A process for making opioid receptor regulators and opioid receptor regulators made by him
IL169575A0 (en) Calcium-sensing receptor antagonist compounds and pharmaceutical compositions containing the same
IL177665A0 (en) Novel pharmaceutical compositions comprising agonists of the thyroid receptor
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
AU2003251705A1 (en) Idol derivatives as new thyroid receptor agonist ligands and methods
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
EP1937223A4 (en) PELLET FORMULATION OF AN ALPHA1 RECEPTOR ANTAGONIST WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF
SI2091938T1 (sl) Piperidinilamino-piridazini in njihova uporaba kot hitro disociirajoči antagonisti dopamin 2 receptorja
IL176485A0 (en) Agonist anti-trkc antibodies and methods using same
GB0203412D0 (en) 5-HT 2B receptor antagonists
AU2003280675A1 (en) SELECTIVE HUMAN Beta3 ADRENALIN RECEPTOR AGONIST AGENT
HUP0200057A3 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
ZA200705206B (en) Toll like receptor 3 antagonists, methods and uses
ZA200704791B (en) Tablets for the sustained release of indapamide and preparation method thereof
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
GB0408398D0 (en) Leptin receptor agonists (3)
IL166080A0 (en) Sustained-release tablet composition comprising a dopamine receptor agonist
GB0408453D0 (en) Leptin receptor agonists
HK1071685B (en) Pharmaceutical composition comprising an s1p receptor agonist